CD274 and neoplasm: We observed considerable variation in tumor responses among mice within treatment groups, particularly in the RT plus anti–PD-L1 and ATRi QDx3 plus RT plus anti–PD-L1 treatment arms, with a number of mice in each arm reaching the survival endpoint (tumor volume >1,000 mm3) much sooner than other mice within that group (Supplemental Figure 8).